ArticleJournal of clinical laboratory analysis2016
Evaluation of the Alere NT-proBNP Test for Point of Care Testing.
Article in Journal of clinical laboratory analysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Acceptability of Cardiovascular Disease Point-of-Care Diagnostics in Primary Care Settings: A Scoping Review.Health science reports · 2026Review
- Melatonin and Comorbidities in Children with Autism Spectrum Disorder.Current developmental disorders reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe object of the study was to evaluate the Alere point of care NT-proBNP assay as a suitable alternative to the central laboratory method to provide short test turnaround times in primary care.
methodBlood NT-proBNP results obtained with the Alere assay (n = 100) were compared with serum NT-proBNP results analyzed by a Cobas 8000 analyzer (Roche Diagnostics, Mannheim, Germany).
resultsThere was a good agreement between the two NT-proBNP methods when used as a rule-out test for heart failure (HF) and the cut-off value <300 ng/l. A total of 47 samples gave values <300 ng/L with both methods and 51 samples gave values >300 with both methods. Thus, there was an agreement for 98% of the samples.
conclusionsThe study shows that the Alere NT-proBNP assay could be used in primary care permitting rapid NT-proBNP testing to rule out HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.